Bionano Genomics (BNGO) Notes Payables (2023 - 2026)

Bionano Genomics has disclosed Notes Payables across 4 years of filings, most recently posting $10.2 million for Q1 2026.

• Notes Payables for Q1 2026 came in at $10.2 million, down 22.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.2 million (down 22.15% YoY), and the FY2025 annual result was $10.0 million, down 50.99% from the prior year.
• Notes Payables came in at $10.2 million for Q1 2026 at Bionano Genomics, up from $10.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $69.8 million in Q4 2023 to a low of $9.8 million in Q3 2025.
• The 4-year median for Notes Payables is $14.0 million (2024), against an average of $20.8 million.
• Across the five-year window, Notes Payables plunged 70.83% in 2024 and decreased 22.15% in 2026, its largest moves.
• Bionano Genomics' Notes Payables stood at $69.8 million in 2023, then slumped by 70.83% to $20.4 million in 2024, then tumbled by 50.99% to $10.0 million in 2025, then advanced by 1.73% to $10.2 million in 2026.
• The last three Notes Payables figures came in at $10.2 million (Q1 2026), $10.0 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.